EULAR Recommendations: Targeted Therapy in Inflammatory Arthritis and Cancer History

<p>A new episode focusses on the recently published 2024 EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer.</p><p>This importnat guideline provides practical advice for rheumatologists navigating the complexities of managing patients with both inflammatory arthritis like rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis,and a past cancer diagnosis.</p><p>In this episode, we&#39;ll delve into key aspects of these recommendations, including:</p><p>• The importance of assessing the individualized risk of cancer recurrence,</p><p>• The necessity of co-management with oncology specialists and shared decision-making with patients,</p><p>• The recommendation to initiate appropriate targeted antirheumatic treatment without delay in patients with cancer in remission,</p><p>• Guidance on managing patients with active IA and a malignancy that is not in remission.</p><p>This episode is for rheumatologists, oncologists, primary care physicians, and anyone involved in the care of patients with inflammatory arthritis and a history of cancer. Understanding these 2024 EULAR points to consider can help enhance therapeutic decision-making and optimize patient outcomes.</p><p>This episode is based to the publication <a href="https://www.sciencedirect.com/science/article/pii/S0003496725000019" target="_blank" rel="noopener noreferer">Sebbag E, et al.Ann Rheum Dis 2025;84:388-397</a></p><p>and was developed with NotebookLM.</p>